These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

680 related articles for article (PubMed ID: 29149804)

  • 1. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
    Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL
    Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Śladowska K; Kawalec P; Holko P; Osiecka O
    Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
    Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
    Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R; Harty G; Wong SL
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
    Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
    Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Lambe T; Duarte R; Mahon J; Nevitt S; Greenhalgh J; Boland A; Beale S; Kotas E; McEntee J; Pomeroy I
    Pharmacoeconomics; 2019 Mar; 37(3):345-357. PubMed ID: 30328051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
    BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
    McCool R; Wilson K; Arber M; Fleetwood K; Toupin S; Thom H; Bennett I; Edwards S
    Mult Scler Relat Disord; 2019 Apr; 29():55-61. PubMed ID: 30677733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis.
    Piasecka-Stryczyńska K; Kaczyński Ł; Rolka M; Homa M; Staśkiewicz W; Paczwa P; Wójcik R; Kaczor MP; Rejdak K
    Neurol Neurochir Pol; 2022; 56(6):480-489. PubMed ID: 36421066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
    Freeman L; Longbrake EE; Coyle PK; Hendin B; Vollmer T
    CNS Drugs; 2022 Dec; 36(12):1285-1299. PubMed ID: 36350491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
    Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis.
    Lees S; Dicker M; Ku JE; Chaganti V; Mew-Sum M; Wang N; Smith A; Oldmeadow C; Goon WL; Bevan M; Lang D; Hinwood M
    BMJ Open; 2021 Nov; 11(11):e051509. PubMed ID: 34728450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cladribine vs other drugs in MS: Merging randomized trial with real-life data.
    Signori A; Saccà F; Lanzillo R; Maniscalco GT; Signoriello E; Repice AM; Annovazzi P; Baroncini D; Clerico M; Binello E; Cerqua R; Mataluni G; Perini P; Bonavita S; Lavorgna L; Zarbo IR; Laroni A; Pareja-Gutierrez L; La Gioia S; Frigeni B; Barcella V; Frau J; Cocco E; Fenu G; Clerici VT; Sartori A; Rasia S; Cordioli C; Stromillo ML; Di Sapio A; Pontecorvo S; Grasso R; Barone S; Barrilà C; Russo CV; Esposito S; Ippolito D; Landi D; Visconti A; Sormani MP
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32801167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.
    Fogarty E; Schmitz S; Tubridy N; Walsh C; Barry M
    Mult Scler Relat Disord; 2016 Sep; 9():23-30. PubMed ID: 27645339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
    Sorensen PS; Pontieri L; Joensen H; Heick A; Rasmussen PV; Schäfer J; Ratzer R; Pihl CE; Sellebjerg F; Magyari M
    Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
    Pinheiro B; Guerreiro R; Costa J; Miguel LS
    J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
    Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan KW; Rieckmann P; Comi G; Dangond F; Hicking C; Vermersch P
    Mult Scler; 2019 May; 25(6):819-827. PubMed ID: 29716436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
    Fernández Ó
    Mult Scler Relat Disord; 2017 Oct; 17():75-83. PubMed ID: 29055479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Li H; Hu F; Zhang Y; Li K
    J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis.
    Liu Z; Liao Q; Wen H; Zhang Y
    Autoimmun Rev; 2021 Jun; 20(6):102826. PubMed ID: 33878488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.